1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
20 citations
,
May 2023 in “Cancer Nanotechnology” The new drug delivery system effectively targets lung cancer cells.
17 citations
,
April 2023 in “Aging” CNGA3, GLUD1, and SIRT1 are promising targets for treating aging and glioblastoma.
July 2025 in “International Journal of Trichology” Oral tofacitinib may effectively regrow hair in children with alopecia areata unresponsive to other treatments.
7 citations
,
March 2011 in “Hormone and Metabolic Research” Certain gene variations might help protect against insulin resistance and glucose intolerance in people with Polycystic Ovary Syndrome.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
October 2025 in “Electronic Theses and Dissertations Repository (University of Pisa)” Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology”
32 citations
,
July 2001 in “Endocrine Practice” Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.
6 citations
,
January 2017 in “Dermato-endocrinology” ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.
January 2026 in “Skin Appendage Disorders” Hair shedding is common in GLP-1 users, affecting treatment adherence.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
July 2025 in “Indian Dermatology Online Journal” Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
October 2025 in “Communications Medicine” Combining genetic and physical data improves diagnosis and treatment for early-onset monogenic diabetes.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
173 citations
,
July 2012 in “British Journal of Dermatology” Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.